Pretest - Tumor Board Tuesday - December 14, 2021 (ID: i788-23)

Question Title

* 1. Please list your first name, last name, and email:

First name:

Last name:

Email:

Question Title

* 2. What is your specialty?

Question Title

* 3. How many patients with metastatic gastric cancer do you treat each week?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 4. The following biomarkers are actionable in advanced esophagogastric cancer except:

dMMR

HER2 mutation

EGFR amplification

PDL1 overexpression

Question Title

* 5. The addition of immunotherapy to chemotherapy in the 1st line Rx of advanced esophagogastric cancer significantly improves PFS and OS irrespective of PDL1 CPS:

True

False